Clinical Trials Logo

Clinical Trial Summary

G/GEJ adenocarcinoma is one of the most common malignant tumors in China, ranking the fifth highest incidence and third highest mortality worldwide. Currently, surgical resection is the preferred treatment for G/GEJ adenocarcinoma, while the 5-year survival rate of patients is lower than 25%. Compared with surgical resection, immunotherapy is proved to be able to effectively prolong the survival time of patients. On one hand, with the continuous promotion of immunotherapy drugs, the exploration of neoadjuvant application of immunotherapy in G/GEJ adenocarcinoma has become a hotspot in recent years. It's also on their way that clinical trials of programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1) and other immune checkpoints are carried out. On the other hand, the research found that although the curative effect of immune therapy seems better, the present G/GEJ adenocarcinoma immunotherapy marker researches mainly focused on the late stage of the cancer, with few studies of immune markers of neoadjuvant therapy for G/GEJ adenocarcinoma. Additionally, it's not quite feasible for single biomarkers to predict the immune treatment effect precisely. Therefore, combined with clinicopathology and therapeutic effects, this study is aimed to construct the efficacy prediction model of anti-PD-1 antibody together with chemotherapy for G/GEJ adenocarcinoma, by detecting RNA expression. Furthermore, this study will perform drug sensitivity test and bio-molecular test on patient derived organoid model to validate the biomarkers found from biological specimens.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05508399
Study type Observational
Source Xijing Hospital
Contact Gang Ji, Doctoral
Phone +8618153227717
Email xijingweichang@163.com
Status Recruiting
Phase
Start date July 18, 2022
Completion date July 18, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT06130332 - Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) Phase 2
Recruiting NCT06250894 - Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction Phase 2
Recruiting NCT04778956 - Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT05741021 - A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 2
Not yet recruiting NCT04284202 - PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC Phase 2
Recruiting NCT04615988 - Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Active, not recruiting NCT04906044 - Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer Phase 1
Not yet recruiting NCT04690036 - PD-1 Antibody for Reactive EBV After BMT Early Phase 1
Recruiting NCT05980715 - PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy Phase 3
Recruiting NCT04840355 - Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
Recruiting NCT04191252 - Genetic Mutation in Epithelial Ovarian Cancer
Recruiting NCT04191226 - Genetic Mutation in Recurrent Cervical Cancer
Not yet recruiting NCT04061928 - Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ Phase 1/Phase 2
Recruiting NCT05979740 - RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Phase 2
Recruiting NCT05980702 - 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC Phase 2
Not yet recruiting NCT04814069 - A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinomaļ¼šThe POTENTIAL Study Phase 2